版权说明 操作指南
首页 > 成果 > 详情

Targeted disruption of the BCR-ABL fusion gene by Cas9/dual-sgRNA inhibits proliferation and induces apoptosis in chronic myeloid leukemia cells.

认领
导出
Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Zeng, Jianling;Liang, Xinquan;Duan, Lili;Tan, Fenghua;Chen, Liujie;...
作者机构:
[Li, Kai; Tan, Fenghua; Chen, Liujie; Li, Jia; Hu, Zheng; Zeng, Jianling; Qu, Jiayao; Duan, Lili; Liang, Xinquan] Translational Medicine Institute, the First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou 423000, China
[Tan, Fenghua; Chen, Liujie; Li, Jia; Hu, Zheng; Zeng, Jianling; Duan, Lili; Liang, Xinquan] The First Affiliated Hospital of Xiangnan University, Chenzhou 423000, China
[Li, Kai] National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Hunan University of Chinese Medicine, Changsha 410208, China
[Luo, Dixian] Department of Laboratory Medicine, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen 518000, China
[Hu, Zheng] National & Local Joint Engineering Laboratory for High-through Molecular Diagnosis Technology, the First People's Hospital of Chenzhou, Chenzhou 423000, China
语种:
英文
关键词:
CRISPR/Cas9;apoptosis;cell proliferation;chronic myeloid leukemia (CML);dual sgRNA
期刊:
生物化学与生物物理学报
ISSN:
1672-9145
年:
2024
机构署名:
本校为其他机构
摘要:
The BCR-ABL fusion gene, formed by the fusion of the breakpoint cluster region protein ( BCR) and the Abl Oncogene 1, Receptor Tyrosine Kinase ( ABL) genes, encodes the BCR-ABL oncoprotein, which plays a crucial role in leukemogenesis. Current therapies have limited efficacy in patients with chronic myeloid leukemia (CML) because of drug resistance or disease relapse. Identification of novel strategies to treat CML is essential. This study aims to explore the efficiency of novel CRISPR-associated protein 9 (Cas9)/dual-single guide RNA (sgRNA)-mediated disruption of the BCR-ABL fusion gene by t...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com